A selection of our portfolio

Developing transformative medicines for patients living with debilitating and life-threatening neurodegenerative disorders

Developing activators of free fatty acid receptors to treat metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH)

Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians

Their next-generation integrated physiological and digital biomarker platform can monitor diseases of the central nervous system at home – providing feedback on disease progression and response to treatment

Developing ETX-810 to treat chronic pain, and ETX-155, to treat major depressive disorder, perimenopausal depression and focal onset seizures. LifeArc invested alongside RA Capital, Intermediate Capital Group, Access Biotechnology, Samlyn Capital and Acorn Bioventures in a $60 million Series B financing in May 2021.

Developing novel, differentiated gene therapies for eye conditions, including diabetic macular oedema, age-related macular degeneration (AMD) and intra-ocular hypertension

Discovering and developing small molecules to promote remyelination to treat multiple sclerosis

Surgery Hero is a virtual program that helps people prepare their mind and body for surgery through sustainable lifestyle changes.